LitCovid-sentences  

PMC:7029759 / 11525-13230 JSONTXT 13 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T72 0-53 Sentence denotes Repurposing currently available antiviral medications
T73 54-221 Sentence denotes Ideal agents to fight 2019-nCoV would be approved small molecule drugs that could inhibit different aspects of the viral life cycle, ultimately inhibiting replication.
T74 222-422 Sentence denotes Two classes of potential targets are viral polymerases 28 and protease inhibitors 29, both of which are components of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) antiviral regimens.
T75 423-534 Sentence denotes Pilot clinical studies are already ensuing by desperate clinicians with various repurposed antiviral medicines.
T76 535-638 Sentence denotes This has been done in every viral outbreak previously with limited success, outside of case reports 30.
T77 639-796 Sentence denotes Indeed, during the Ebola outbreak, none of the repurposed small molecule drugs were definitively shown to improve the clinical course across all patients 31.
T78 797-1034 Sentence denotes The 2019-nCoV could be different, and there are initial positive reports that lopinavir and ritonavir, which are HIV protease inhibitors, have some clinical efficacy against 2019-nCoV, similar to prior studies using them against SARS 32.
T79 1035-1279 Sentence denotes Research should continue to be undertaken to screen other clinically available antivirals in cell culture models of 2019-nCoV, in hopes that a drug candidate would emerge useful against the virus that could be rapidly implemented in the clinic.
T80 1280-1421 Sentence denotes One promising example could be remdesivir, which interferes with the viral polymerase and has shown efficacy against MERS in mouse models 33.
T81 1422-1530 Sentence denotes For further information, reviews of previous drug repurposing efforts for coronaviruses are provided 34, 35.
T82 1531-1705 Sentence denotes Though these repurposed medications may hold promise, it is still reasonable to pursue novel, 2019-nCoV specific therapies to complement potential repurposed drug candidates.